GAIA AG

Our customers face significant challenges in managing chronic conditions and mental health disorders, which is why we at GAIA AG are dedicated to revolutionizing healthcare through evidence-based digital therapeutics. We understand that patients and healthcare providers need accessible, effective, and safe treatment options that seamlessly integrate into daily life. Founded in 1997, our mission has always been to empower individuals globally and improve patient outcomes through the adept use of scalable technology. By bridging the gap between traditional medicine and state-of-the-art digital solutions, we provide physicians, therapists, payers, and patients with the same effect sizes, similar safety profiles, and equal levels of convenience as found in well-developed pharmaceutical solutions.

Our patients often struggle with the accessibility and consistency of traditional therapies, which is why our digital therapeutics are designed to be fully automated, personalized, and available anytime, anywhere. We have forged a legacy of innovation, pioneering patient-centric treatments for conditions such as depression, multiple sclerosis, immunology, and rheumatology. Our flagship products, like deprexis®, have been rigorously tested in numerous randomized controlled trials (RCTs) to ensure clinically validated effectiveness. We firmly believe that digital therapeutics unlock a new era in healthcare, where AI-powered, data-driven solutions redefine disease management. By actively collaborating with pharmaceutical companies, medical device organizations, and healthcare providers, we accelerate progress and expand our reach to make a meaningful, lasting impact on the global healthcare landscape. Ultimately, our goal is to support as many people as possible in restoring and maintaining their mental and physical health, thereby elevating their overall quality of life.